PL2504332T3 - Amorficzna i krystaliczna forma hemiwinianu genz 112638 jako inhibitor syntazy glukozyloceramidowej - Google Patents

Amorficzna i krystaliczna forma hemiwinianu genz 112638 jako inhibitor syntazy glukozyloceramidowej

Info

Publication number
PL2504332T3
PL2504332T3 PL10785289T PL10785289T PL2504332T3 PL 2504332 T3 PL2504332 T3 PL 2504332T3 PL 10785289 T PL10785289 T PL 10785289T PL 10785289 T PL10785289 T PL 10785289T PL 2504332 T3 PL2504332 T3 PL 2504332T3
Authority
PL
Poland
Prior art keywords
genz
hemitartrate
amorphous
inhibitor
crystalline form
Prior art date
Application number
PL10785289T
Other languages
English (en)
Other versions
PL2504332T5 (pl
Inventor
Hanlan Liu
Chris Willis
Renu Bhardwaj
Diane P Copeland
Abizer Harianawala
Jeffrey Skell
John Marshall
Jianmei Kochling
Gerard Palace
Judith Peterschmitt
Craig Siegel
Seng Cheng
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43431870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2504332(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of PL2504332T3 publication Critical patent/PL2504332T3/pl
Publication of PL2504332T5 publication Critical patent/PL2504332T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Molecular Biology (AREA)
  • Steroid Compounds (AREA)
PL10785289T 2009-11-27 2010-11-24 Amorficzna i krystaliczna postać hemiwinianu genz 112638 jako inhibitor syntazy glukozyloceramidowej PL2504332T5 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26474809P 2009-11-27 2009-11-27
EP10785289.9A EP2504332B2 (en) 2009-11-27 2010-11-24 An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
PCT/US2010/057952 WO2011066352A1 (en) 2009-11-27 2010-11-24 An amorphous and a crystalline form of genz 112638 hemitartrat as inhibitor of glucosylceramide synthase

Publications (2)

Publication Number Publication Date
PL2504332T3 true PL2504332T3 (pl) 2014-10-31
PL2504332T5 PL2504332T5 (pl) 2021-08-23

Family

ID=43431870

Family Applications (4)

Application Number Title Priority Date Filing Date
PL19182732T PL3599237T3 (pl) 2009-11-27 2010-11-24 Kompozycja farmaceutyczna inhibitora syntazy glukozyloceramidowej eliglustatu do leczenia choroby Gauchera obejmującego dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 pacjenta
PL14164650T PL2796457T3 (pl) 2009-11-27 2010-11-24 Genz 112638 do leczenia w terapii skojarzonej choroby Gauchera lub choroby Fabry’ego
PL16175117T PL3133070T3 (pl) 2009-11-27 2010-11-24 Eliglustat (Genz 112638) jako inhibitor syntazy glukozyloceramidowej do zastosowania w sposobie leczenia choroby Fabry’ego lub choroby Gauchera, przy czym sposób obejmuje dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 u pacjenta
PL10785289T PL2504332T5 (pl) 2009-11-27 2010-11-24 Amorficzna i krystaliczna postać hemiwinianu genz 112638 jako inhibitor syntazy glukozyloceramidowej

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PL19182732T PL3599237T3 (pl) 2009-11-27 2010-11-24 Kompozycja farmaceutyczna inhibitora syntazy glukozyloceramidowej eliglustatu do leczenia choroby Gauchera obejmującego dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 pacjenta
PL14164650T PL2796457T3 (pl) 2009-11-27 2010-11-24 Genz 112638 do leczenia w terapii skojarzonej choroby Gauchera lub choroby Fabry’ego
PL16175117T PL3133070T3 (pl) 2009-11-27 2010-11-24 Eliglustat (Genz 112638) jako inhibitor syntazy glukozyloceramidowej do zastosowania w sposobie leczenia choroby Fabry’ego lub choroby Gauchera, przy czym sposób obejmuje dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 u pacjenta

Country Status (40)

Country Link
US (6) US11458119B2 (pl)
EP (5) EP3599237B1 (pl)
JP (6) JP2013512252A (pl)
KR (6) KR20200013105A (pl)
CN (5) CN102712629B (pl)
AR (3) AR079152A1 (pl)
AU (3) AU2010324810B2 (pl)
BR (1) BR112012012947B8 (pl)
CA (3) CA3140959A1 (pl)
CL (2) CL2012001348A1 (pl)
CR (1) CR20120277A (pl)
CY (3) CY1115880T1 (pl)
DK (3) DK2796457T3 (pl)
DO (2) DOP2012000141A (pl)
EA (3) EA023923B1 (pl)
EC (2) ECSP12011926A (pl)
ES (4) ES2754398T3 (pl)
GT (1) GT201200161A (pl)
HR (3) HRP20140780T4 (pl)
HU (2) HUE029371T2 (pl)
IL (4) IL310635A (pl)
LT (2) LT3133070T (pl)
MA (1) MA33838B1 (pl)
ME (1) ME02477B (pl)
MX (2) MX381242B (pl)
MY (2) MY192644A (pl)
NI (1) NI201200096A (pl)
NZ (3) NZ715108A (pl)
PE (2) PE20121337A1 (pl)
PH (2) PH12015502514B1 (pl)
PL (4) PL3599237T3 (pl)
PT (4) PT3599237T (pl)
RS (3) RS53503B2 (pl)
SG (2) SG10201407881WA (pl)
SI (3) SI3133070T1 (pl)
SM (1) SMT201600273B (pl)
TN (1) TN2012000237A1 (pl)
TW (3) TWI656873B (pl)
UA (1) UA113491C2 (pl)
WO (1) WO2011066352A1 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889127B2 (en) 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
MX381242B (es) 2009-11-27 2025-03-12 Genzyme Corp Una forma amorfa y una cristalina de hemitartrato de genz 112638 como inhibidor de glucosilceramida sintasa.
JP6175431B2 (ja) * 2011-06-20 2017-08-02 アイカーン スクール オブ メディシン アット マウント サイナイ ムコ多糖症およびその他のリソソーム障害に対する抗ｔｎｆ療法
WO2013036875A1 (en) 2011-09-07 2013-03-14 Mount Sinai School Of Medicine Ceramidase and cell differentiation
WO2013078413A1 (en) * 2011-11-22 2013-05-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulators of lipid storage
EP3679923B1 (en) 2012-06-01 2021-08-04 Icahn School of Medicine at Mount Sinai Ceramide levels in the treatment and prevention of infections
EP3659619A1 (en) 2013-03-14 2020-06-03 Icahn School of Medicine at Mount Sinai Therapeutic acid ceramidase compositions and methods of making and using them
MX374452B (es) * 2013-09-20 2025-03-06 Biomarin Pharm Inc Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
WO2016001885A2 (en) * 2014-07-03 2016-01-07 Dr. Reddy’S Laboratories Limited Amorphous form of eliglustat hemitartarate
WO2016166170A1 (en) 2015-04-14 2016-10-20 Sandoz Ag Crystalline eliglustat hydrochloride
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
JP6895963B2 (ja) 2015-11-18 2021-06-30 ジェンザイム・コーポレーション 多発性嚢胞腎のバイオマーカーおよびその使用
ES2879351T3 (es) 2016-02-25 2021-11-22 Asceneuron Sa Sales de derivados de piperazina obtenidas por adición de ácidos
CN107445938B (zh) * 2016-05-31 2020-04-03 北京启慧生物医药有限公司 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物
CN106349210A (zh) * 2016-08-24 2017-01-25 北京阳光诺和药物研究有限公司 一种制备酒石酸艾力骨司坦的方法
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
WO2018193090A2 (en) * 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof
ZA201803719B (en) 2017-06-05 2019-04-24 Cipla Ltd Stable solid dispersions of eliglustat hemitartrate
TW201904577A (zh) * 2017-06-16 2019-02-01 美商貝達醫藥公司 N-(2-(2-二甲胺基)乙氧基)-4-甲氧基-5-((4-(1-甲基-1h-吲哚-3-基)嘧啶-2-基)胺基)苯基)丙烯醯胺及其鹽之醫藥調配物
WO2019030645A1 (en) 2017-08-08 2019-02-14 Kashiv Pharma Llc Pharmaceutical composition comprising eliglustat
US12472144B2 (en) * 2017-08-08 2025-11-18 Amneal Pharmaceuticals Llc Pharmaceutical composition comprising eliglustat
KR102791275B1 (ko) * 2017-12-15 2025-04-08 젠자임 코포레이션 고쉐병의 치료 방법
WO2019123476A1 (en) * 2017-12-20 2019-06-27 Sarudbhava Formulations Private Limited Stable amorphous eliglustat premix and process for the preparation thereof
US11760741B2 (en) 2018-05-02 2023-09-19 Kashiv Biosciences, Llc Pro-drugs of eliglustat
JP2021525711A (ja) * 2018-05-27 2021-09-27 バイオアシス テクノロジーズ インコーポレイテッド ゴーシェ病の処置
CN110878079A (zh) * 2018-12-31 2020-03-13 北京启慧生物医药有限公司 一种高纯度依利格鲁司他的制备方法
AU2021455177B2 (en) * 2021-07-05 2025-01-09 Asceneuron Sa Medicaments comprising glycosidase inhibitors
CN116120274A (zh) * 2021-11-12 2023-05-16 曙方(上海)医药科技有限公司 依利格鲁司他可药用盐及其晶型

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311286D0 (en) 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
DE3522475A1 (de) 1985-06-22 1987-01-02 Kali Chemie Pharma Gmbh Neue aromatische verbindungen, ihre herstellung und verwendung
US5041441A (en) 1988-04-04 1991-08-20 The Regents Of The University Of Michigan Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
ZA929008B (en) 1991-12-13 1993-05-21 Bristol Myers Squibb Co Piperazinyl- and piperidinyl-cyclohexanols.
US5302609A (en) 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
ATE197672T1 (de) 1993-08-13 2000-12-15 Seikagaku Kogyo Co Ltd Arzneimittel gegen nervöse erkrankungen
US6309823B1 (en) 1993-10-26 2001-10-30 Affymetrix, Inc. Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same
JPH09508900A (ja) 1994-02-02 1997-09-09 ザ リポソーム カンパニー、インコーポレーテッド 薬理学的に活性な化合物及びリポソーム並びにそれらの使用方法
CN1152907A (zh) 1994-06-10 1997-06-25 生化学工业株式会社 2-酰胺基丙醇化合物及其药物组合物
FR2734819B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant
US5916911A (en) 1995-09-20 1999-06-29 The Regents Of The University Of Michigan Amino ceramide--like compounds and therapeutic methods of use
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6255336B1 (en) 1995-09-20 2001-07-03 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6890949B1 (en) 1999-07-09 2005-05-10 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20030073680A1 (en) 1995-09-20 2003-04-17 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
JP3993908B2 (ja) 1995-12-08 2007-10-17 生化学工業株式会社 アミノアルコール誘導体及び該誘導体の製造方法
NO965193L (no) 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
JP4140984B2 (ja) 1995-12-20 2008-08-27 生化学工業株式会社 分化誘導作用を有する薬剤
US5972928A (en) 1997-05-21 1999-10-26 Johns Hopkins University Methods for treatment of conditions associated with lactosylceramide
JP4036500B2 (ja) 1997-05-23 2008-01-23 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
JP4176170B2 (ja) 1997-06-06 2008-11-05 生化学工業株式会社 アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
WO2000006145A1 (en) 1998-07-27 2000-02-10 Johns Hopkins University Methods for treating conditions modulated by lactosylceramide
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
BR0012318A (pt) * 1999-07-09 2002-05-28 Univ Michigan Compostos semelhantes a amino ceramida e métodos terapêuticos de uso
AU2930501A (en) * 2000-01-07 2001-07-24 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
US20040252299A9 (en) 2000-01-07 2004-12-16 Lemmo Anthony V. Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
SK16372002A3 (sk) 2000-04-24 2003-04-01 Teva Pharmaceutical Industries Ltd. Zolpidem hemitartrát
US6436987B1 (en) 2000-06-08 2002-08-20 Pfizer Inc. Crystalline forms of (3S-trans)-2-[3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl]-4-(trifluoromethyl)-benzoic acid
US7148251B2 (en) 2001-01-10 2006-12-12 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20020198240A1 (en) 2001-01-10 2002-12-26 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
WO2002062777A2 (en) 2001-01-10 2002-08-15 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20040260099A1 (en) 2001-01-10 2004-12-23 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO2002057435A2 (en) * 2001-01-18 2002-07-25 Merck Patent Gmbh Bifunctional fusion proteins with glucocerebrosidase activity
ES2399323T3 (es) 2001-07-16 2013-03-27 Genzyme Corporation Síntesis de inhibidores de la UDP-glucosa:N-acilesfingosina glucosiltransferasa
EP1281755A3 (en) 2001-07-31 2003-06-18 Pfizer Products Inc. Variants of the human cyp2d6 gene
WO2003014105A1 (en) 2001-08-08 2003-02-20 Takeda Chemical Industries, Ltd. Bicyclic compound, production and use as hiv inhibitors
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US20060217560A1 (en) 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
WO2004004702A2 (en) 2002-07-09 2004-01-15 The Scripps Research Institute Method to inhibit ischemia and reperfusion injury
US20050032070A1 (en) 2003-08-05 2005-02-10 Sebastian Raimundo Polymorphisms in the human gene for CYP2D6 and their use in diagnostic and therapeutic applications
EP1709053B1 (en) * 2004-01-27 2011-04-06 Synthon B.V. Stable salts of olanzapine
KR20070054246A (ko) 2004-09-17 2007-05-28 유니버시티 오브 매사추세츠 리소좀성 효소 결핍을 위한 조성물 및 이의 용도
EP2479290B1 (en) 2004-09-30 2020-08-19 Vanda Pharmaceuticals Inc. Methods for the administration of iloperidone
US8324230B2 (en) 2004-10-13 2012-12-04 Pfizer Inc. Crystalline forms of 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-Yl]-N-(2-hydroxyethyl)-4-methylbenzamide
WO2006053043A2 (en) 2004-11-10 2006-05-18 Genzyme Corporation Methods of treating diabetes mellitus
WO2007038676A2 (en) * 2005-09-28 2007-04-05 Teva Pharmaceutical Industries Ltd. Polymorphic forms of ladostigil tartrate
CN101277959A (zh) * 2005-10-03 2008-10-01 马林克罗特公司 制备唑吡坦半酒石酸盐和酒石酸盐多晶型的方法
MX2007016179A (es) 2006-04-17 2008-03-11 Teva Pharma Formas cristalinas de o-desmetilvenlafaxina.
HUE026057T2 (en) 2006-05-09 2016-05-30 Genzyme Corp Procedures for the Treatment of Fatty Liver Disease, which comprises inhibition of glycosphingolipid synthesis
KR101271225B1 (ko) 2006-10-31 2013-06-03 삼성디스플레이 주식회사 발광 다이오드 칩 및 발광 다이오드 광원 모듈의 제조 방법
TWI314226B (en) 2006-12-07 2009-09-01 Ind Tech Res Inst Piezoelectricity-driving optical lens module
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
PE20081632A1 (es) * 2007-01-12 2008-12-10 Wyeth Corp Composiciones de tableta en tableta
AU2008232614A1 (en) * 2007-03-30 2008-10-09 Amicus Therapeutics, Inc. Method for the treatment of Fabry disease using pharmacological chaperones
US9056101B2 (en) * 2007-04-26 2015-06-16 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
EP2167485B1 (en) 2007-05-31 2015-09-30 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
DE102007029581B4 (de) 2007-06-26 2020-04-09 GM Global Technology Operations LLC (n. d. Ges. d. Staates Delaware) Kraftfahrzeugdach und Kraftfahrzeugkarosserie
US20090307180A1 (en) 2008-03-19 2009-12-10 Brandon Colby Genetic analysis
WO2009117150A2 (en) * 2008-03-20 2009-09-24 Genzyme Corporation Method of treating lupus with ceramide derivatives
KR101861981B1 (ko) 2009-11-27 2018-05-28 아드베리오 파마 게엠베하 제약상 물질로서 사용하기 위한 메틸-(4,6-디아미노-2-(1-(2-플루오로벤질)-1ｈ-피라졸로(3,4-ｂ)피리디노-3-일)피리미디노-5-일)메틸카르바메이트의 제조 방법 및 그의 정제
FR2953139B1 (fr) 2009-11-27 2012-04-13 Servier Lab Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine
EP3646859A1 (en) 2009-11-27 2020-05-06 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
MX381242B (es) 2009-11-27 2025-03-12 Genzyme Corp Una forma amorfa y una cristalina de hemitartrato de genz 112638 como inhibidor de glucosilceramida sintasa.
JP2014517049A (ja) 2011-06-21 2014-07-17 ノバルティス アーゲー （ｓ）−ピロリジン−１，２−ジカルボン酸２−アミド１−（｛４−メチル−５−［２−（２，２，２−トリフルオロ−１，１−ジメチル−エチル）−ピリジン−４−イル］−チアゾール−２−イル｝−アミドの多形
JO3316B1 (ar) 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
JP6728842B2 (ja) 2016-03-24 2020-07-22 オムロン株式会社 光学計測装置
CN107445938B (zh) 2016-05-31 2020-04-03 北京启慧生物医药有限公司 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物
WO2018193090A2 (en) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof

Also Published As

Publication number Publication date
PL3133070T3 (pl) 2020-01-31
US20160166542A1 (en) 2016-06-16
HRP20140780T4 (hr) 2021-08-06
US11458119B2 (en) 2022-10-04
US20210369672A1 (en) 2021-12-02
RS53503B2 (sr) 2021-07-30
IL283935A (en) 2021-07-29
LT3133070T (lt) 2019-11-11
NZ600155A (en) 2014-10-31
CA3075788A1 (en) 2011-06-03
ECSP12011926A (es) 2012-07-31
AU2017265180B2 (en) 2019-08-01
SI2504332T2 (sl) 2021-08-31
PT2796457T (pt) 2016-07-14
SI3133070T1 (sl) 2019-11-29
SG10201800136QA (en) 2018-02-27
PL2504332T5 (pl) 2021-08-23
TW201130822A (en) 2011-09-16
ME02477B (me) 2017-02-20
EA023923B1 (ru) 2016-07-29
CN112521366A (zh) 2021-03-19
CN102712629B (zh) 2016-10-12
IL260299A (en) 2018-08-30
EA201270646A1 (ru) 2013-01-30
LT2796457T (lt) 2016-09-12
NZ625712A (en) 2016-02-26
PE20121337A1 (es) 2012-10-12
EA201890254A2 (ru) 2018-10-31
HK1203485A1 (en) 2015-10-30
US12465586B2 (en) 2025-11-11
EA029990B1 (ru) 2018-06-29
CN102712629A (zh) 2012-10-03
RS54978B1 (sr) 2016-11-30
AU2016202591B2 (en) 2017-11-30
PT2504332E (pt) 2014-09-02
EP2504332B1 (en) 2014-06-04
ES2493940T5 (es) 2021-11-23
CA3140959A1 (en) 2011-06-03
IL219892A0 (en) 2012-07-31
EP2504332A1 (en) 2012-10-03
BR112012012947B8 (pt) 2021-05-25
US20130137743A1 (en) 2013-05-30
TW201737910A (zh) 2017-11-01
JP2013512252A (ja) 2013-04-11
EP3133070A1 (en) 2017-02-22
CN105753846B (zh) 2019-11-15
SI2796457T1 (sl) 2016-10-28
US20210393590A1 (en) 2021-12-23
TWI606827B (zh) 2017-12-01
AR121611A2 (es) 2022-06-22
CN105777707A (zh) 2016-07-20
SI2504332T1 (sl) 2014-09-30
CN105777707B (zh) 2020-10-13
HUE045784T2 (hu) 2020-01-28
JP2016138124A (ja) 2016-08-04
DK3133070T3 (da) 2019-11-11
JP2020189873A (ja) 2020-11-26
US20230172903A1 (en) 2023-06-08
CA2781676C (en) 2020-05-05
AR079152A1 (es) 2011-12-28
AU2017265180A1 (en) 2017-12-14
MX381242B (es) 2025-03-12
ES2754398T3 (es) 2020-04-17
CL2016002589A1 (es) 2017-05-19
TWI586663B (zh) 2017-06-11
AR121612A2 (es) 2022-06-22
HRP20161038T1 (hr) 2016-10-21
TN2012000237A1 (en) 2013-12-12
RS59543B1 (sr) 2019-12-31
CY1115880T1 (el) 2017-01-25
KR20200013105A (ko) 2020-02-05
ES2875382T3 (es) 2021-11-10
KR20250005503A (ko) 2025-01-09
BR112012012947B1 (pt) 2021-04-06
EP2504332B2 (en) 2021-03-17
IL310635A (en) 2024-04-01
ES2493940T3 (es) 2014-09-12
HUE029371T2 (en) 2017-02-28
PT3599237T (pt) 2021-04-28
RS53503B1 (sr) 2015-02-27
EP3133070B1 (en) 2019-08-14
HK1172031A1 (en) 2013-04-12
WO2011066352A1 (en) 2011-06-03
JP6370264B2 (ja) 2018-08-08
DOP2012000141A (es) 2012-09-30
WO2011066352A8 (en) 2011-08-11
PL3599237T3 (pl) 2021-09-27
CN112521367A (zh) 2021-03-19
EA201890254A3 (ru) 2019-02-28
GT201200161A (es) 2014-01-27
ECSP18063798A (es) 2020-02-28
US10888547B2 (en) 2021-01-12
KR20120115972A (ko) 2012-10-19
JP2015212291A (ja) 2015-11-26
EP3599237B1 (en) 2021-03-24
AU2016202591A1 (en) 2016-05-19
CR20120277A (es) 2012-09-05
CN112521367B (zh) 2024-01-02
SMT201600273B (it) 2016-08-31
NI201200096A (es) 2012-10-30
MA33838B1 (fr) 2012-12-03
BR112012012947A2 (pt) 2017-03-01
KR20180049255A (ko) 2018-05-10
NZ715108A (en) 2017-06-30
JP2023116764A (ja) 2023-08-22
EP3599237A1 (en) 2020-01-29
CY1117996T1 (el) 2017-05-17
JP6452635B2 (ja) 2019-01-16
DOP2016000250A (es) 2017-02-15
CY1122698T1 (el) 2021-03-12
SG10201407881WA (en) 2015-01-29
US20160120842A1 (en) 2016-05-05
DK2504332T3 (da) 2014-08-25
TWI656873B (zh) 2019-04-21
JP7150528B2 (ja) 2022-10-11
DK2504332T4 (da) 2021-06-07
DK2796457T3 (en) 2016-08-29
EP2796457B1 (en) 2016-05-18
PT3133070T (pt) 2019-11-11
KR20220162824A (ko) 2022-12-08
JP2019001809A (ja) 2019-01-10
AU2010324810A1 (en) 2012-06-07
KR102073207B1 (ko) 2020-02-05
MX358345B (es) 2018-08-14
PE20171255A1 (es) 2017-08-28
UA113491C2 (xx) 2017-02-10
EA201592195A1 (ru) 2016-04-29
KR20150125734A (ko) 2015-11-09
PH12015502514A1 (en) 2016-08-15
AU2010324810B2 (en) 2016-05-12
CN105753846A (zh) 2016-07-13
CA2781676A1 (en) 2011-06-03
PH12015502514B1 (en) 2022-07-29
MX2012006083A (es) 2012-06-19
HRP20140780T1 (en) 2014-11-07
MY160542A (en) 2017-03-15
EP2796457A1 (en) 2014-10-29
MY192644A (en) 2022-08-29
EP3896069A1 (en) 2021-10-20
PL2796457T3 (pl) 2017-04-28
HRP20191647T1 (hr) 2019-12-13
CA3075788C (en) 2021-12-21
TW201639562A (zh) 2016-11-16
CL2012001348A1 (es) 2012-08-24
PH12012501048A1 (en) 2013-02-04
ES2586947T3 (es) 2016-10-19

Similar Documents

Publication Publication Date Title
IL260299A (en) Crystalline and amorphous form of genz 112638 hemitartrate as an inhibitor of glucosylceramide synthase
IL210322A0 (en) Crystalline salts of sitagliptin
SI2155200T1 (sl) Kristalinična oblika kabamoil-cikloheksanskega derivata
SG10201400926VA (en) Inhibition of biofilm organisms
IL243058A0 (en) Amorphous salt of macrocyclic hcv inhibitor
PT2611779T (pt) Formas cristalinas de um inibidor do fator xa
IL221198A0 (en) Crystalline salts of a potent hcv inhibitor
ZA201105045B (en) Crystalline forms of genistein
SI2358676T1 (sl) Kristalinična oblika 4-(2-(2-fluorofenoksimetil)fenil)piperidinske spojine
IL216202A0 (en) PROCESS FOR THE PREPARATION OF A COMPOUND USEFUL AS AN INHIBITOR OF TAFIa
EP2439202A4 (en) INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1
ZA201104319B (en) Crystalline forms of a 3-carboxypropyl-aminotetralin compound
AP2717A (en) Mono-hydrochloric salts of an inhibitor of histonedeacetylase
PT2413949T (pt) Inibição de organismos de biofilmes